Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

为落实「健康台湾」政策，力拚癌症死亡率下降三分之一目标，健保署宣布通过3种癌症免疫疗法给付，包括「非鳞状非小细胞肺癌第一线」、「转移性大肠直肠癌第一线」及「早期三阴性乳癌」，预估嘉惠3400名病患，病人一年最高可省247万元，最快今年6月生效。

Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

An immunotherapy treatment could ‘change the world’ for newly diagnosed head and neck cancer patients by giving them an extra ...

Investing.com — Summit Therapeutics Inc. (NASDAQ: SMMT )股价暴跌37%，此前该公司应中国卫生当局要求公布的临时分析显示，其药物Ivonescimab与Pembrolizumab相比在PD-L1阳性晚期非小细胞肺癌 (NSCLC)治疗中呈现积极趋势，但未能消除投资者的疑虑。